Avalo Therapeutics, Inc. (AVTX)
13.65
+0.22
(+1.64%)
USD |
NASDAQ |
Oct 09, 16:00
13.65
0.00 (0.00%)
After-Hours: 20:00
Avalo Therapeutics Enterprise Value : 324.01M for Oct. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 09, 2026 | 324.01M |
| October 08, 2026 | 312.37M |
| October 07, 2026 | 320.31M |
| October 06, 2026 | 320.84M |
| October 05, 2026 | 374.27M |
| October 02, 2026 | 394.90M |
| October 01, 2026 | 392.78M |
| September 30, 2026 | 412.88M |
| September 29, 2026 | 426.11M |
| September 28, 2026 | 399.66M |
| September 25, 2026 | 420.29M |
| September 24, 2026 | 433.52M |
| September 23, 2026 | 411.30M |
| September 22, 2026 | 475.31M |
| September 21, 2026 | 457.32M |
| September 18, 2026 | 478.48M |
| September 17, 2026 | 484.83M |
| September 16, 2026 | 479.01M |
| September 15, 2026 | 452.03M |
| September 14, 2026 | 457.85M |
| September 11, 2026 | 454.68M |
| September 10, 2026 | 510.75M |
| September 09, 2026 | 565.24M |
| September 08, 2026 | 644.59M |
| September 04, 2026 | 619.20M |
| Date | Value |
|---|---|
| September 03, 2026 | 607.03M |
| September 02, 2026 | 625.02M |
| September 01, 2026 | 604.39M |
| August 31, 2026 | 625.02M |
| August 28, 2026 | 638.24M |
| August 27, 2026 | 662.58M |
| August 26, 2026 | 689.03M |
| August 25, 2026 | 646.18M |
| August 24, 2026 | 621.31M |
| August 21, 2026 | 650.94M |
| August 20, 2026 | 650.41M |
| August 19, 2026 | 699.61M |
| August 18, 2026 | 644.59M |
| August 17, 2026 | 657.29M |
| August 14, 2026 | 638.24M |
| August 13, 2026 | 630.84M |
| August 12, 2026 | 636.13M |
| August 11, 2026 | 631.89M |
| August 10, 2026 | 647.76M |
| August 07, 2026 | 571.06M |
| August 06, 2026 | 591.16M |
| August 05, 2026 | 598.57M |
| August 04, 2026 | 582.17M |
| August 03, 2026 | 556.77M |
| July 31, 2026 | 567.35M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AbbVie, Inc. | 552.84B |
| Rezolute, Inc. | 362.63M |
| ACADIA Pharmaceuticals, Inc. | 2.522B |
| Alnylam Pharmaceuticals, Inc. | 30.80B |
| Anika Therapeutics, Inc. | 248.88M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -36.36M |
| Total Expenses (Quarterly) | 36.36M |
| EPS Diluted (Quarterly) | -0.8339 |
| Earnings Yield | -34.72% |
| Normalized Earnings Yield | -30.79 |